Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Financing Activities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Cash from Financing Activities for 13 consecutive years, with -$80000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 102.13% to -$80000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, up 28.81% year-over-year, with the annual reading at $6.9 million for FY2025, 28.81% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$80000.0 at Niagen Bioscience, down from $148000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $33.4 million in Q1 2021, with the low at -$80000.0 in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $2.8 million, with a median of $105500.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities soared 90291.89% in 2021, then tumbled 1300.0% in 2024.
  • Over 5 years, Cash from Financing Activities stood at $63000.0 in 2021, then soared by 12088.89% to $7.7 million in 2022, then tumbled by 100.99% to -$76000.0 in 2023, then skyrocketed by 5031.58% to $3.7 million in 2024, then tumbled by 102.13% to -$80000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$80000.0, $148000.0, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.